Ileus Clinical Trial
— INTEGRITYOfficial title:
A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of LB1148 in Accelerating the Time to Return of Bowel Function in Subjects Undergoing Planned Bowel Resection (INTEGRITY)
Verified date | April 2024 |
Source | Palisade Bio |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the safety and efficacy of LB1148 in subjects undergoing planned bowel resection.
Status | Terminated |
Enrollment | 23 |
Est. completion date | August 11, 2023 |
Est. primary completion date | March 6, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: Subjects will be eligible for participation in the study only if they meet ALL of the following inclusion criteria: 1. Adults age 18 to 80 years, inclusive. 2. Scheduled to undergo a planned (non-emergent) bowel resection via minimally invasive technique or laparotomy. This includes any subject in which a resection of the small intestine, colon, or rectum is performed for any elective indication. 3. Willing to perform and comply with all study procedures including, being hospitalized until achieving GI-2 and responding to telephone follow-up visits as scheduled. 4. Willing and able to provide written informed consent. Exclusion Criteria: Subjects will not be eligible for participation in the study if they meet ANY of the following exclusion criteria: 1. History of total colectomy. 2. Has a preexisting ostomy. 3. History of radiation enteritis. 4. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2. 5. History of seizure disorder. 6. History of myeloproliferative disorders. 7. American Society of Anesthesiologists (ASA) Class IV or V. 8. Inability to take IP orally or consume solid food. 9. Planned treatment with alvimopan (EnteregĀ®) during hospitalization period 10. Chronic opioid usage, defined by the American Pain Society as daily or near-daily use of opioids for at least 90 days. 11. Men and women of child bearing potential (WOCBP) who are unwilling to practice a highly effective method of contraception that may include, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with vasectomized partner, vasectomy, hysterectomy, bilateral tubal ligation, licensed hormonal methods (but not combination hormonal methods), intrauterine device, or use of spermicide combined with a barrier method (e.g., condom, diaphragm) for 28 days before Day 1 and through Day 30. 12. Women who will not agree to stop combined hormonal contraceptive and or combined hormonal replacement therapy (including combined hormonal pill, patch or vaginal ring) during the 7 day period prior to Surgery (Study Day 2) through the 7 day period following surgery (Study Days 3 through 9). 13. Has contraindications or potential risk factors to taking TXA. These include subjects with: - Known sensitivity to TXA - Recent craniotomy (past 30 days) - Active cerebrovascular bleed - Active thromboembolic disease (such as deep vein thrombosis, pulmonary embolism, cerebral thrombosis, ischemic stroke, or acute coronary syndrome) - Acute promyelocytic leukemia taking all-trans retinoic acid for remission induction 14. Receipt of any investigational drug within 28 days or 5 half-lives prior to Day 1. 15. Any other condition that, in the opinion of the Investigator would make the subject unsuitable for the study or unable to comply with the study requirements. |
Country | Name | City | State |
---|---|---|---|
United States | Site 321 | Baltimore | Maryland |
United States | Site 359 | Bridgeport | Connecticut |
United States | Site 324 | Burlington | Massachusetts |
United States | Site 318 | Chapel Hill | North Carolina |
United States | Site 351 | Clearwater | Florida |
United States | Site 313 | Columbus | Ohio |
United States | Site 320 | Dallas | Texas |
United States | Site 355 | Grand Rapids | Michigan |
United States | Site 319 | Houston | Texas |
United States | Site 357 | Iowa City | Iowa |
United States | Site 358 | Jacksonville | Florida |
United States | Site 354 | La Jolla | California |
United States | Site 331 | Miami | Florida |
United States | Site 315 | Mobile | Alabama |
United States | Site 317 | New York | New York |
United States | Site 356 | New York | New York |
United States | Site 329 | Orange | California |
United States | Site 353 | Providence | Rhode Island |
United States | Site 325 | Rochester | Minnesota |
United States | Site 352 | Saint Louis | Missouri |
United States | Site 326 | Salt Lake City | Utah |
United States | Site 350 | San Diego | California |
United States | Site 312 | Torrance | California |
Lead Sponsor | Collaborator |
---|---|
Palisade Bio |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to Return of Gastrointestinal Function | The later of the times in hours from placement of the last skin staple or suture to the time of toleration of solid food (defined as the time a subject finished a meal that required chewing and experienced no significant nausea/vomiting for 4 hours after the solid meal) and the first bowel movement, up to 14 days post-surgery | From surgical procedure up to 14 days in hospital | |
Secondary | Time to First Bowel Movement | Time in hours from placement of the last skin staple or suture to the time of first bowel movement | From surgical procedure up to 14 days in hospital | |
Secondary | Time Subject is Ready for Discharge | Time subject is ready for discharge, defined as the time from the end of surgery to the time the subject is ready for hospital discharge solely based on the recovery of GI function, as determined by the surgeon | From surgical procedure up to 14 days in hospital | |
Secondary | Time Discharge Order Written | Time discharge order written, defined as the time from the end of surgery to the time that the hospital discharge order is written | From surgical procedure up to 14 days in hospital | |
Secondary | Time of Actual Discharge | Time of actual discharge, defined as the time from the end of surgery to the time the subject is actually discharged from the hospital | From surgical procedure up to 14 days in hospital |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00065234 -
Acupuncture to Prevent Postoperative Bowel Paralysis (Paralytic Ileus)
|
Phase 2 | |
Completed |
NCT01156129 -
Interventions to Decrease the Impact of Post-OPerative Ileus After Liver Transplant or Resection Surgery
|
Phase 1 | |
Recruiting |
NCT05712525 -
Gut Recovery In Patients Following Surgery
|
||
Completed |
NCT06338813 -
Digital Manometry for Intra-Abdominal Pressure Measurement in Ileus
|
N/A | |
Recruiting |
NCT05315765 -
Development of a Patient Reported Outcome Measure for GastroIntestinal Recovery
|
||
Completed |
NCT02161367 -
Effect of Simethicone on Postoperative Ileus in Patients Undergoing Colorectal Surgery
|
Phase 4 | |
Completed |
NCT03711487 -
The Effect of Foeniculum Vulgare Ironing on Gastrointestinal Recovery After Colorectal Resection
|
Phase 2 | |
Completed |
NCT00528970 -
A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair
|
Phase 3 | |
Not yet recruiting |
NCT04001985 -
Nasogastric Tube Clamping Trial vs. Immediate Removal
|
N/A | |
Completed |
NCT02836470 -
A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection
|
Phase 2 | |
Completed |
NCT04100447 -
A Study to Evaluate the Safety, Tolerability and Efficacy of LB1148 for Subjects Undergoing Elective Bowel Resection
|
Phase 1 | |
Active, not recruiting |
NCT03795467 -
Peripheral Perfusion Index, Haemoglobin and Blood Transfusion in Acute Surgical Patients
|
||
Completed |
NCT01143259 -
Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use
|
N/A | |
Terminated |
NCT03352414 -
Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC
|
Phase 2 | |
Not yet recruiting |
NCT04305730 -
Use of Pedometer Following Radical Cystectomy
|
N/A | |
Completed |
NCT02760290 -
Comparison of Extraperitoneal and Intraperitoneal Cesarean Technique
|
N/A | |
Active, not recruiting |
NCT02399605 -
Subcutaneous Electrical Stimulation in the Prevention of Postoperative Ileus
|
N/A | |
Completed |
NCT00388258 -
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus
|
Phase 3 | |
Completed |
NCT00205842 -
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus
|
Phase 3 | |
Enrolling by invitation |
NCT05298774 -
Myoelectric Activity Following Colorectal Surgery and Return of Bowel Function
|
N/A |